OZOW
28.7.2020 07:02:12 CEST | Business Wire | Press release
“In a constantly changing global economy, traditionally dominated by large banks since 1472, (something which is unlikely to change in the coming decades), Ozow is positioned as a disruptor to challenge the status quo. Ozow is leading the way with an Open Banking platform in Africa, and the startling growth of the business over the past 6 years tells the story of a fast growing start up on the verge of taking the African continent by storm,” says Ozow CEO and co-founder, Thomas Pays. “As a market led company Ozow’s success has grown to see them capturing an entire market (representing over 70% of the instant EFT market in South Africa), from the heart of underprivileged townships and rural areas to the highest LSM. Users all note that the payment platform is a better, safer, and easier alternative to cards or a manual EFT payment ”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005804/en/
There are over 49 million bank accounts in South Africa alone – users just need a convenient way to pay from them. This is where Ozow’s secure online payments platform is leading payment innovation.
“Consumers, merchants, and banks in South Africa and Namibia now recognize Ozow as the quick and trusted way to make payments,” says Pays. “As most people in the region go online mainly through their mobile devices (the same rings true for the rest of Africa) – and often pre-pay for airtime/data – transaction speed is essential. We commit to enabling payments in a few seconds.”
Ozow’s latest product release in the form of a world first, patent-pending innovation called the Ozow PIN has also resulted in increased growth of the business. This technology empowers a user to tokenize payment and make any repeat purchases with the simple entry of a 4-digit PIN. This world first innovation is already aggressively taking the lion’s share of the cash, card, and alternative payment options market by empowering users to transact anytime, anywhere online, or at point of sale, without the need for an app or registration. “As a market leading payments company in Africa, we have put the needs of our clients first, resulting in an increase of over 50% in recurring payments since the introduction of this new technology,’’ says Pays. Ozow can also be used for e-billing in partnership with SAGE and Xero, SMS payments via all major networks, and QR codes. The service is becoming available in five of South Africa’s 11 official languages, with plans to add the other languages in the coming months.
From the merchant’s perspective, Ozow acts as an additional layer of security to that of the existing banking infrastructure, keeping all transactions ultra-safe at all times and providing an environment that has proven to be safer than any other payment mechanism. Once a payment has been confirmed, it is irrevocable, using a real-time digital instruction issued by the owner of the source account.
Ozow was founded in 2014 by Mitchan Adams and Lyle Eckstein (both South African) together with CEO Thomas Pays , a Frenchman who has lived in South Africa for more than 16 years.
The past few years has seen Ozow become the most trusted payment brand among users who have developed a strong emotional attachment to the brand, empowering many to transact digitally for the first time.
Ozow’s company values and the culture it has developed focuses on empowering its stakeholders and being impactful. In April last year Ozow introduced a “0% fees’’ campaign for NPO/NGO’s as well as SME’s, again leading the way in the market as a socially responsible business, by passing value on to entrepreneurs (a critical element of the South African economy) who often place their customer’s needs ahead of their own.
“Today, Ozow is a team of 50 + people who share a vision of bringing our fast and easy payment solutions to the African continent and ultimately the globe. Through Ozow, in a market where over ZAR9,7 trillion is transferred via “bank to bank” payments a year, well over 11 times the market share of card payments, the prospect of financial inclusion for all is virtually limitless,” says Pays.
“Our approach is completely open, and we want to partner with banks and other payments providers in each of the markets we enter,” he says. “We’ve taken the time to make sure our tech is ready for scalability, and we believe that moment has now arrived.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005804/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
